Bayer's MRI Contrast Agent Gets Panel Endorsement, But Without Comparative Safety Claims

FDA's Peripheral and Central Nervous System Drugs Advisory Committee declines to deem gadobutrol "lower risk" for causing nephrogenic systemic fibrosis.